IMR Press / RCM / Volume 25 / Issue 1 / DOI: 10.31083/j.rcm2501021
Open Access Original Research
Clinical Effect of the Modified Morrow Septal Myectomy Procedure for Biventricular Hypertrophic Cardiomyopathy
Show Less
1 Department of Cardiovascular Surgery, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510000 Guangzhou, Guangdong, China
2 Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vascular Diseases, 10029 Beijing, China
*Correspondence: guohuiming@gdph.org.cn (Huiming Guo)
These authors contributed equally.
Rev. Cardiovasc. Med. 2024, 25(1), 21; https://doi.org/10.31083/j.rcm2501021
Submitted: 10 August 2023 | Revised: 1 September 2023 | Accepted: 10 September 2023 | Published: 10 January 2024
(This article belongs to the Section Cardiovascular Intervention and Therapeutics)
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Right ventricular involvement in hypertrophic cardiomyopathy is uncommon. This study aimed to evaluate clinical outcomes of the modified septal myectomy in patients diagnosed with biventricular hypertrophic cardiomyopathy (BHCM), a subject seldom explored in the literature. Methods: We conducted a retrospective cohort study from January 2019 to January 2023, enrolling 12 patients with BHCM. Each patient underwent a modified septal myectomy and was followed postoperatively. Clinical data and echocardiographic parameters, including the ventricular outflow tract peak pressure gradient and maximum interventricular septum thickness, were collected and analyzed. Results: The study cohort had a median age of 43.0 (interquartile range 14.5–63.0) years at surgery, with four patients (33.3%) being children. Two patients (16.7%) previously underwent percutaneous transluminal septal myocardial ablation. Surgical relief of biventricular outflow tract obstruction (BVOTO) was achieved in five patients (41.7%), aside from those managed solely for left ventricular outflow tract obstruction. In five instances, three-dimensional (3D) printing technology assisted in surgical planning. The postoperative interventricular septum thickness was significantly reduced (21.0 mm preoperative vs. 14.5 mm postoperative, p < 0.001), effectively eliminating residual ventricular outflow tract obstruction. There were no severe complications, such as septal perforation or third-degree atrioventricular block. During a mean follow up of 21.2 ± 15.3 months, no sudden deaths, residual outflow tract obstruction, permanent pacemaker implantation, recurrent systolic anterior motion, or reoperations were reported. Conclusions: Our findings affirm that the modified septal myectomy remains the gold standard treatment for BHCM, improving patient symptoms and quality of life. BVOTO relief can be safely and effectively achieved through septal myectomy via transaortic and pulmonary valve approaches in selected patients. For intricate cases, the application of 3D printing technology as a preoperative planning tool is advised to optimize surgical precision and safety.

Keywords
hypertrophic obstructive cardiomyopathy
biventricular hypertrophic cardiomyopathy
ventricular outflow tract obstruction
biventricular outflow tract obstruction
modified septal myectomy
clinical analysis
3D printing
Funding
2020B1111170011/Science and Technology Planning Project of Guangdong Province
202201010768/Science and Technology Program of Guangzhou
2020XXG010/Cardiovascular Special Project of Guangdong Provincial People’s Hospital
2022A1515010157/National Natural Science Foundation of Guangdong
2023P-ZD09/Clinical High-Tech and Major Technologies of Guangzhou
Guangdong special funds for Science and Technology Innovation Strategy
Figures
Fig. 1.
Share
Back to top